Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.36 |
| ▸ | HTT | P42858 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895675 | 0.75 | KAT2B (0.39) | LIMK1IKBKBCHUKKDM4EMAPT | |
| SCHEMBL2976564 | 0.75 | KAT2B (0.39) | LIMK1IKBKBCHUKKDM4EMAPT | |
| SCHEMBL492415 | 0.75 | NPC1 (0.43) | LIMK1IKBKBCHUKKDM4EMAPT | |
| SCHEMBL4158596 | 0.75 | MAPT (0.50) | LIMK1IKBKBCHUKKDM4EMAPT | |
| SCHEMBL493004 | 0.75 | L3MBTL1 (0.46) | LIMK1IKBKBCHUKKDM4EMAPT | |
| SCHEMBL492026 | 0.73 | KDM4E (0.47) | LIMK1IKBKBCHUKKDM4EMAPT | |
| SCHEMBL24835668 | 0.71 | GRM4 (0.43) | KDM4EMAPTHSP90AA1L3MBTL1NPC1 | |
| SCHEMBL18879061 | 0.71 | CYP2A6 (0.36) | LIMK1IKBKBCHUKKDM4EMAPT | |
| SCHEMBL12603987 | 0.71 | GRM4 (0.40) | LIMK1IKBKBCHUKKDM4EMAPT | |
| SCHEMBL492512 | 0.71 | KDM4E (0.34) | LIMK1IKBKBCHUKKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582709-B1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI SA (FR) | 2018-01-24 | — | — | EP | disclosed |
| US-8933024-B2 | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-01-13 | — | — | US | disclosed |
| US-8933024-B2 | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-01-13 | — | — | US | disclosed |
| US-8933024-B2 | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-01-13 | — | — | US | disclosed |
| US-8921404-B2 | Azole derivatives in the form of lipase and phospholipase inhibitors | SANOFI (FR) | 2014-12-30 | — | — | US | disclosed |
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| EP-2582709-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011157827-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157827-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2011-12-22 | — | — | WO | disclosed |
| US-20080090867-A1 | Antidiabetic agents; compounds have insulin-like effect; optionally ring C4-7 aza-substituted 3-substituted benzisoxazoles or benzisothiazoles; 1-(2-Methylbenzyl)-3-(5-nitrobenzo[d]isothiazol-3-yl)urea for example | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090867-A1 | Antidiabetic agents; compounds have insulin-like effect; optionally ring C4-7 aza-substituted 3-substituted benzisoxazoles or benzisothiazoles; 1-(2-Methylbenzyl)-3-(5-nitrobenzo[d]isothiazol-3-yl)urea for example | FABP4, GPR119, LIPE | LIMK1 3292/4885IKBKB 164/4885CHUK 62/4885 |
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LPL, CEL | LIMK1 2121/4885IKBKB 1890/4885CHUK 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.